Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours are Epidermal Growth Factor Receptor 2 (HER-2) Amplified or Co-Expressing Epidermal Growth Factor Receptor 1 (HER-1) and HER 2
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2015
At a glance
- Drugs Varlitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals; PharmaNet Development Group
- 07 Jun 2017 Biomarkers information updated
- 08 Aug 2013 According to an Array BioPharma media release, positive results of this trial were reported in gastric cancer and a phase 2b study will be conducted.
- 07 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01614522).